ACGT® - Scientifc Advisory Council - Stephen L. Eck, M.D., Ph.D.

Scientific Advisory Council

Stephen L. Eck, M.D., Ph.D.
Vice President
Translational Medicine & Pharmacogenomics
Eli Lilly and Company
Indianapolis, IN

Dr. Eck earned his doctorate in synthetic organic chemistry at Harvard
University before joining a tumor angiogenesis research program at
Monsanto Corporation. He subsequently earned his M.D. degree with
specialized training in Internal Medicine and Hematology and Oncology
(University of Michigan). He joined the faculty at the University of
Pennsylvania in 1993 as the Ann B. Young Assistant Professor of Medicine
and Director of the Cancer Gene Therapy Programs.

While at the University of Pennsylvania, he worked on a number of gene
therapy and immunotherapy translational research projects. In 2002, he
joined Pfizer Global Research and Development in their Oncology
Therapeutic Area. He has served in several roles encompassing early and
full development, including serving as the Clinical Site Head for
Neuroscience and Oncology.

He later was appointed Vice President of Molecular Medicine, a global
group within Pfizer that seeks to develop more precision therapeutics
through the application of pharmacogenomics, proteomics, metabonomics
and RNA profiling and as Vice President of Translational Medicine. In
2007 he joined Eli Lilly & Company as Vice President of Translational
Medicine & Pharmacogenomics. In this role he is responsible for Lilly's
studies of genetic contributions to diseases and drug response, and for
the implementation of studies that bring new medicines with novel
mechanism of action into clinical testing.

< Return to Scientific Advisory Council

Home | About ACGT | Contact ACGT | Site Contents | Privacy Policy